- Home
- ORGO vs CGEM Comparison
ORGO vs CGEM Comparison
Compare ORGO & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORGO
- CGEM
- Stock Information
- Founded
- ORGO 1985
- CGEM 2016
- Country
- ORGO United States
- CGEM United States
- Employees
- ORGO N/A
- CGEM N/A
- Industry
- ORGO Biotechnology: Pharmaceutical Preparations
- CGEM Biotechnology: Pharmaceutical Preparations
- Sector
- ORGO Health Care
- CGEM Health Care
- Exchange
- ORGO Nasdaq
- CGEM Nasdaq
- Market Cap
- ORGO 465.6M
- CGEM 482.7M
- IPO Year
- ORGO N/A
- CGEM 2021
- Fundamental
- Price
- ORGO $4.89
- CGEM $8.19
- Analyst Decision
- ORGO Buy
- CGEM Strong Buy
- Analyst Count
- ORGO 2
- CGEM 7
- Target Price
- ORGO $7.50
- CGEM $26.57
- AVG Volume (30 Days)
- ORGO 642.5K
- CGEM 364.2K
- Earning Date
- ORGO 08-07-2025
- CGEM 08-07-2025
- Dividend Yield
- ORGO N/A
- CGEM N/A
- EPS Growth
- ORGO N/A
- CGEM N/A
- EPS
- ORGO N/A
- CGEM N/A
- Revenue
- ORGO $429,531,000.00
- CGEM N/A
- Revenue This Year
- ORGO $2.57
- CGEM N/A
- Revenue Next Year
- ORGO $9.80
- CGEM N/A
- P/E Ratio
- ORGO N/A
- CGEM N/A
- Revenue Growth
- ORGO N/A
- CGEM N/A
- 52 Week Low
- ORGO $2.46
- CGEM $6.85
- 52 Week High
- ORGO $6.71
- CGEM $19.89
- Technical
- Relative Strength Index (RSI)
- ORGO 59.08
- CGEM 56.95
- Support Level
- ORGO $4.41
- CGEM $6.89
- Resistance Level
- ORGO $4.90
- CGEM $8.08
- Average True Range (ATR)
- ORGO 0.30
- CGEM 0.40
- MACD
- ORGO -0.03
- CGEM 0.05
- Stochastic Oscillator
- ORGO 92.58
- CGEM 92.20
About ORGO Organogenesis Holdings Inc.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.